Cancer immunotherapy: Macs in the middle

Naglaa H Shoukry; Simon Turcotte

doi:10.1016/j.immuni.2021.02.012

Cancer immunotherapy: Macs in the middle

Immunity. 2021 Mar 9;54(3):409-411. doi: 10.1016/j.immuni.2021.02.012.

Authors

Naglaa H Shoukry¹, Simon Turcotte²

Affiliations

¹ Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada; Institut du cancer de Montréal, Montréal, Québec, Canada; Département de médecine, Faculté de médecine, Université de Montréal, Montréal, Québec, Canada. Electronic address: naglaa.shoukry@umontreal.ca.
² Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada; Institut du cancer de Montréal, Montréal, Québec, Canada; Service de chirurgie hépatobiliaire et pancréatique et de transplantation hépatique du Centre hospitalier de l'Université de Montréal, Montréal, Québec, Canada.

PMID: 33691132
DOI: 10.1016/j.immuni.2021.02.012

Abstract

Response to immune checkpoint blockade cancer immunotherapy is variable, but the mechanisms that underlie this variability remain unclear. In a recent issue of Nature Medicine, Yu et al. demonstrate that liver metastases limit immunotherapy efficacy by promoting macrophage-mediated elimination of tumor-specific CD8⁺ T cells. Liver-directed radiotherapy in preclinical models could partially overcome this effect.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

CD8-Positive T-Lymphocytes*
Humans
Immunotherapy
Neoplasms* / therapy